Prof Thomas Powles speaks to ecancer about the interim analysis from the JAVELIN Bladder 100 phase III trial looking at maintenance avelumab plus best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma, presented at the 2020 ASCO Virtual Meeting.
He explains that the study enrolled 700 patients who have stable disease or have responded to front line chemotherapy, they were then randomised to avelumab plus best supportive care or best supportive care alone.
Prof Powles reports that after a median follow up of 19 months the median overall survival for the avelumab arm was 21 months compared with 14 months for best supportive care alone.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Read more about the study here.